[182 Pages Report] The global superdisintegrants market is projected to reach USD 536.5 million by 2023 from USD 366.4 million in 2018, at a CAGR of 7.9% during the forecast period. The increasing adoption of orally disintegrating tablets, the growing generics market, and the emergence of new superdisintegrants for the pharmaceutical industry are factors driving the market for superdisintegrants. The shifting focus of pharmaceutical manufacturing to emerging markets and the growth of the overall pharmaceutical market in these markets present significant opportunities for market growth. However, safety and quality concerns are expected to challenge the growth of the superdisintegrants market to a certain extent during the forecast period.

By type, crospovidone segment to grow at the highest CAGR

This crospovidone segment is also expected to grow at the highest CAGR during the forecast period due to its wide use in fast-disintegrating oral solid dosage forms.

By formulation, tablets segment is expected to be the largest market during the forecast period

This market is also estimated to grow at a higher rate during the forecast period. The large share of this segment can be attributed to the widespread use of ODTs and fast-disintegrating tablets among healthcare providers and patients, resulting in the large-scale manufacture of these products by pharmaceutical manufacturers. The high demand for such ODTs and FDTs can be attributed to their advantages such as increasing drug bioavailability, better pre-gastric absorption, ease of swallowing in patients with dysphagia, ease of administration, and improved shelf-life.

By geography, Asia Pacific (APAC) to register the highest growth rate during the forecast period

With significant growth in pharmaceutical manufacturing in the past few years, China and India have emerged as high-growth markets for superdisintegrants. Other than APAC countries, Brazil also shows significant growth potential for the superdisintegrants market. A majority of this growth is driven by the significant growth in the healthcare market as well as the pharmaceutical industry in these regions. The low-cost manufacturing advantage, increasing per capita income, and low regulatory stringency are also factors supporting the growth of the superdisintegrants market in these regions.

Market Dynamics

Driver: Emergence of new superdisintegrants for the pharmaceutical industry

The preparation of special blends of superdisintegrants is an important development in the pharmaceutical industry. With these preparations, manufacturers now have access to a variety of superdisintegrants, including co-processed excipients which consist of a combination of synthetic and natural superdisintegrants or several synthetic superdisintegrants or synthetic superdisintegrants with other pharmaceutical excipients. This helps to improve the functioning of drugs due to the quick functioning of the active ingredients. Disintegrants are specially formulated for use in the direct compression method of tablet formulations that removes a number of processing steps used in wet and dry granulation. Orally disintegrating tablets (ODTs) are one of the fastest-growing drug delivery forms using superdisintegrants for direct compression.

Growth in the adoption of novel excipients is also increasingly being supported by a favorable regulatory environment in the developed regions. The International Pharmaceutical Excipients Council (IPEC) has encouraged the development and use of new excipients. The council has developed a novel excipient evaluation procedure as an independent process to decrease the cost and ambiguity related to the use of novel excipients in pharmaceutical formulations. This is expected to increase the demand for superdisintegrants in the pharmaceutical industry.

Opportunity: Pharmaceutical market expansion in emerging countries

The traditionally lucrative pharmaceuticals market is becoming challenging from a growth perspective due to the diminishing drug pipeline, government pressures to curtail healthcare costs, and the increasing regulations on innovative products. This is encouraging pharmaceutical manufacturers to move their manufacturing bases closer to high-growth emerging markets. Through this, manufacturers can take advantage of the low-cost manufacturing along with several financial benefits in terms of attractive tax rates and lenient regulatory guidelines for manufacturing in these countries. A number of major excipient manufacturers are either planning capacity expansions of their existing plants in emerging countries or setting up new manufacturing plants in emerging markets such as China and India.

Challenge:Safety and quality concerns

Despite the growing use of excipients in pharmaceuticals, the superdisintegrants industry faces the challenge of meeting the quality expectations of regulators, end users, drug makers, and more importantly, patients. Variations in superdisintegrant production affect drug performance along with its critical quality attributes. Supplier-to-supplier or batch-to-batch variations in superdisintegrant concentrations affect the excipient-drug interaction, in turn affecting drug efficacy and quality.

Furthermore, a large part of the pharmaceutical excipient manufacturing process is outsourced to smaller excipient manufacturers in low-cost countries such as India and China. This leads to low control over the excipient manufacturing process and quality, thereby increasing the need for process transparency in the entire supply chain. However, achieving immediate streamlining and maximum transparency in supply chain activities poses a challenge for both drug manufacturers and excipient manufacturers.

Scope of the Report

Report Metric Details Market size available for years 2016�2023 Base year considered 2017 Forecast period 2018�2023 Forecast units USD million Segments covered Type, Formulation, Therapeutic Area, and Region Geographies covered North America, APAC, Europe, Latin America Middle East & Africa Companies covered BASF SE (Germany), Ashland Global Holdings Inc. (US), DowDuPont (US), Roquette Freres (France), DFE Pharma (Germany), JRS PHARMA (Germany), Asahi Kasei Corporation (Japan), Merck KGaA (Germany), Corel Pharma Chem (India), Avantor Performance Materials (US)

The research report categorizes the Superdisintegrants Market to forecast the revenues and analyze the trends in each of the following sub-segments:

By Type:

Natural Superdisintegrants

Synthetic Superdisintegrants

Other Superdisintegrants

By Formulation

Tablets

Capsules

By Therapeutic Area:

Gastrointestinal Diseases

Neurological Diseases

Oncology

Infectious Diseases

Cardiovascular Diseases

Hematological Diseases

Inflammatory Diseases

By Region

North America

Europe

Asia Pacific (APAC)

Latin America

Middle East and Africa

Key Market Players

BASF SE (Germany), Ashland Global Holdings Inc. (US), DowDuPont (US), Roquette Freres (France)

Recent Developments

In October 2017, Roquette opened a new Pharmaceutical R&D and Customer Technical Service (CTS) in Biopolis (Singapore) for the development of new products and new applications for existing products as well as pre-clinical research. This new facility operates as Roquette�s Asia Pacific headquarters and focuses on food, nutrition, and pharma products.

In March 2017, BASF Group opened the Innovation Campus Asia Pacific in India, marking the company�s largest R&D investment in South Asia. The company invested USD 61.6 million (EUR 50 million) in this center to increase its global and regional research activities.

In October 2016, Ashland opened a new pharmaceutical excipient facility in Nanjing, China, to produce excipients for the Asian market. The company supplies highly functional excipient technologies to manufacturers of oral pharmaceuticals and provide tailor-made formulation solutions through this facility

In June 2016, DuPont opened its ASEAN (Association of Southeast Asian Nations) headquarters in Singapore in an effort to enhance the company�s competitive advantage in pivotal growth markets.

In March 2016, Roquette received the EXCiPACT certification for Good Manufacturing Practices covering the manufacturing, testing, and packaging of a wide number of excipients.

Critical questions the report answers:

Where will all these developments take the superdisintegrants market in the long term?

What are the upcoming trends for the superdisintegrants market?

Which segment in the superdisintegrants market provides the most opportunity for growth?

Who are the leading vendors operating in this superdisintegrants market?

What are the opportunities for new market entrants in the superdisintegrants market?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst